Charles River and Purespring Therapeutics Announce Gene Therapy Manufacturing Collaboration
Thursday, February 16, 2023
Charles River Laboratories International, Inc. and Purespring Therapeutics announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration.
Under the terms of an agreement, Plasmid CDMO alliance supports the first gene therapy platform targeting kidney diseases.
Supporting the first gene therapy platform targeting renal diseases, which affect approximately 840 million people, or around 10 per cent of the global population, the program leverages Charles River’s established plasmid platform, eXpDNA™.
